Deals this week: Ritter Pharmaceuticals, Sienna Biopharmaceuticals, Exscientia
Ritter Pharmaceuticals has announced a public offering of class A units to raise $10m.
The US-based pharmaceutical company plans to use the funds for general corporate purposes, including research and development (R&D) programmes and working capital.
US-based Sienna Biopharmaceuticals plans to raise $74.75m through an initial public offering (IPO) of common stock shares.
Sienna plans to use the funds from the offering towards the development of SNA-120.
Exscientia has formed a strategic partnership with GlaxoSmithKline (GSK) to carry out drug programmes for the latter.
The artificial intelligence-based drug discovery company will undertake programmes aimed at discovering novel and selective small molecules for various targets identified by GSK.
Australian life science company BARD1 Life Sciences has announced two offerings of 137 million common stock shares and 125 million shares priced at A$0.008 ($0.006) a share, to raise a total of A$2m ($1.6m).
BARD1 plans to use the funds towards R&D programmes and for general corporate purposes.